Byron Bay Hinterland, Australia – 02 Dec 20 – Australian Biotech company, CannaPacific, today announced the award of permits enabling the commencement of cultivation, production and research of medicinal cannabis plants at their Byron Bay Hinterland facility.
The permits, granted by the Office of Drug Control, is a major step forward for CannaPacific and represents the culmination of complex planning and hard work.
“The award of these permits is a major achievement for the CannaPacific team. To achieve a permit in this Australian Regulatory environment is extremely difficult and represents several years of extensive planning, construction and substantial investment. We can now fulfill our offtake agreements and expand on our advanced genomic breeding programmes with our partners,” said CEO, Joshua Dennis.
The Northern Rivers facility consists of 10,000 sqm under glass and large outdoor cultivation area protected by the highest level of security.
Under their medical cannabis licence, CannaPacific will produce dried flower for extraction and pharmaceutical production to meet the growing global medicinal cannabis market. The CannaPacific facility also includes a plant research area for variety development in collaboration with R&D partners including the University of Newcastle and Tasmanian Alkaloids.
Cultivation and the development of plant varieties underpins CannaPacific’s strategy by focussing on linking the underlying plant genetics to develop high yielding new cannabis varieties. These new varieties with novel cannabinoid profiles, will be used to support our pharmaceutical development program on pure cannabinoid based medicines.
CannaPacific is licenced and permitted by the Australian Government to cultivate and research medicinal cannabis in an undisclosed location in Northern NSW.
CannaPacific is an Australian biotechnology company focused on the cannabinoid pharmaceutical sector. By combining advanced molecular breeding technology with a traditional approach to drug development, CannaPacific seeks to build a global therapeutic offering with an initial focus on palliative care and post traumatic stress disorder.
CannaPacific’s strategy is to attain a world-leading position in the field of cannabinoid science through the research, development and commercialisation of cannabinoid molecules as authorised pharmaceutical products.
CannaPacific operates a cultivation facility nestled in the beautiful Byron Bay hinterland in northern NSW. The production facility includes a 10,000 sqm Dutch glasshouse and high-security outdoor cultivation area.
About medicinal cannabis:
Governments at both Commonwealth and State and Territory levels have implemented legislative and policy change to allow the cultivation, manufacture, prescribing and dispensing of medicinal cannabis products for patients in Australia. https://www.tga.gov.au/medicinal-cannabis-guidance-documents
Joshua Dennis (CEO)
Ph: +61 427 631 611